Abstract:Currently, the effect of AIDS single-target chemotherapy is severely compromised by the quick emergence of resistant HIV strains. Highly active antiretroviral therapy (HAART) combines HIV reverse transcriptase inhibitors with protease inhibitors or integrase inhibitors, and successfully suppresses HIV viral load to an undetectable level, dramatically improving the life quality of AIDS patients. However, the benefits of this approach are often compromised by poor patient compliance. Recently, there has been a move toward multicomponent drugs whereby two or more agents are coformulated in a single tablet to make dosing regimes simpler and thereby to improve patient compliance, but there are significant risks involved in the development of multicomponent drugs. Designed multiple ligands (DMLs) therapy as an emerging anti-HIV drug discovery paradigm, using a single entity to inhibit multitargets could yield improved patient compliance, thus reducing the likelihood of drug resistance. The exploration of such multifunctional ligands has proven valuable for anti-HIV leads discovery. However, presently many multifunctional scaffolds were first discovered by serendipity or screening; rational design by combining existing monofunctional scaffolds remains an enormous challenge. A key issue in the design of multiple ligands is attaining a balanced activity at each target of interest while simultaneously achieving a wider selectivity and a suitable pharmacokinetic profile. This review of literature examples introduce numerous attractive lead compounds, capable of interfering with different stages of HIV infection and AIDS pathogenesis, which reveals trends and insights that might provide valuable clues for novel anti-HIV drug design and help medicinal chemists discover the next generation of multiple ligands.

Novel strategies in rational design of anti-HIV agents:multitarget and multivalency ligands

Rationally Designed Multitarget Anti-HIV Agents

Designed Multiple Ligands: an Emerging Anti-HIV Drug Discovery Paradigm

Multivalent agents: A novel concept and preliminary practice in anti-hiv drug discovery

Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors

Recent Advances in Computer-aided Antiviral Drug Design Targeting HIV-1 Integrase and Reverse Transcriptase Associated Ribonuclease H

Progress on AIDS drug targets and small molecule inhibitors

"Old Dogs with New Tricks": Exploiting Alternative Mechanisms of Action and New Drug Design Strategies for Clinically Validated HIV Targets.

HIV‐1 NNRTIs: Structural Diversity, Pharmacophore Similarity, and Impliations for Drug Design

[The Application of Structural Optimization Strategies in Drug Design of HIV NNRTIs].

Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends.

"Old Dogs with New Tricks": exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets.

Design strategies of novel NNRTIs to overcome drug resistance.

Medicinal Chemistry Strategies For Discovering Antivirals Effective Against Drug-Resistant Viruses

Pyridin-2(1H)-ones as HIV-1 NNRTIs: a combinatorial optimization strategy

Multitargeted Drug Design Strategy for Discovery of Short-Peptide-based HIV-1 Entry Inhibitors with High Potency

2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies

Design, Synthesis, and Mechanistic Study of 2-Pyridone-bearing Phenylalanine Derivatives As Novel HIV Capsid Modulators

Recent Advances in the Rational Drug Design Based on Multi-target Ligands.

Structure-based design, synthesis, and biological characterization of indolylarylsulfone derivatives as novel human immunodeficiency virus type 1 inhibitors with potent antiviral activities and favorable drug-like profiles

Synthetic approaches and application of clinically approved small-molecule Anti-HIV drugs: An update